KalVista Pharmaceuticals, Inc. Overview
Pro stress-test →KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral protease inhibitors for rare genetic diseases, particularly hereditary angioedema (HAE). The company achieved a major milestone with FDA approval of EKTERLY (sebetralstat) as the first and only oral on-demand treatment for HAE, which launched in 2025 and is driving significant revenue growth.
Strategic Profile
Pro stress-test →KalVista applies deep expertise in the kallikrein-kinin system to develop breakthrough oral medicines that address the full spectrum of HAE management. The company is well-positioned as the only player with an FDA-approved oral on-demand HAE treatment, creating competitive moat potential in a growing rare disease market with limited therapeutic options.
Competitive Landscape
Pro stress-test →KalVista faces limited direct competition in the oral on-demand HAE space due to EKTERLY's unique position. Key competitors include Pharvaris (PHVS) and Pharming Group with alternative HAE treatments, though their approaches differ. The market remains nascent with significant patient populations still underserved, allowing for multiple players despite KalVista's leadership.
Industry Context
KalVista Pharmaceuticals, Inc. operates in Biopharmaceutical - Rare Disease / Specialty Pharma.
Key facts
Headquarters: Framingham, Massachusetts, United States · Employees: 250+